NEW YORK (GenomeWeb) – Perthera and Thomas Jefferson University today announced a collaboration for the use of Perthera's molecularly targeted diagnostics and bioinformatics services and analysis.
Through the collaboration, physicians at Thomas Jefferson University Hospitals facilities and affiliates will be able to use Perthera's products and services to analyze patients' tumors and outcomes data, and in the process, gain a better understanding of the molecular structure of the tumors. Each analysis will be integrated into the McLean, Virginia-based company's Expert Oncologist system, a database that sources current clinical knowledge, research, and drug information "to facilitate [the] analysis of multi-omic molecular profiles in context with the patient's medical history," the partners said.
Perthera combines genomic, proteomic, and phosphoproteomic analysis with a patient's medical history and diagnostic technology to enable physicians to provide individualized treatment of their patients' disease, the company and Thomas Jefferson University said.
After testing is completed, Perthera's medical review panel will analyze and interpret the data to provide actionable therapies and clinical trial options to the doctors and their patients. The company correlates molecular stratification for therapies with outcome results "thus providing a unique registry to validate molecular profiling-based therapies," the partners said.